The results of this prospective study demonstrate the feasibility and safety of PRT for the treatment of newly diagnosed GBM patients. To our knowledge, this is the first study to investigate the use of PRT prospectively and in the definitive management of this patient population. The observed clinical outcomes are promising and compare favorably with those of well-matched patients treated at our institution with SRT as well as to historic controls. The 4 largest randomized trials investigating various treatments for newly diagnosed GBM reported median PFS of 4 to 7.3 months and mOS of 14.6 to 16.1 months in patients receiving concurrent SRT and TMZ, compared with 10.7 and 20.9 months for patients receiving PRT and TMZ on our study.2,3,25,26 Notably, the patient cohort in our study has a slightly higher median age and a higher percentage of patients with subtotal tumor resection compared with all of the aforementioned trials.
All but one of the patients in this study had IDH–WT tumors, and only 3 patients had MGMT methylated tumors. These tumor characteristics portend a poor prognosis. The reported mOS in patients with IDH–WT tumors is in the range of 12 to 15 months.27,28 In a recent randomized trial, which investigated the addition of TTF to maintenance TMZ, patients with MGMT unmethylated tumors receiving SRT and TMZ had mOS of 14.7 months.3 Even the addition of TTF, which has resulted in the highest mOS in GBM patients reported by any major randomized trial to date, did not drastically improve survival in patients with MGMT unmethylated tumors (mOS of 16.9 mo).
Maintenance of QoL and preservation of NCF are important endpoints of treatment, especially in patients with GBM given their poor prognosis and relatively short life span. There are a paucity of longitudinal data on QoL and NCF after definitive treatment in GBM patients. Nonetheless, the existing evidence shows NCF to be an independent predictor of survival in high-grade gliomas and has a strong direct correlation with QoL and the ability to maintain independence and perform daily living activities.29–32 There has been a concerted effort to minimize RT-related NCF, and recent studies have shown promising results in this regard with the addition of memantine and employment of RT techniques that deliberately avoid the hippocampus, which is central to preservation of NCF.33,34 Unfortunately, cognitive decline remains a common complication in long-term GBM survivors.
